**Core tip:** This is the first study to compare the difference in the failure patterns for pT3-4N0-3M0 esophageal squamous cell carcinoma (ESCC) patients with or without postoperative radiotherapy (PORT) after esophagectomy. The result showed that PORT could improve disease-free survival and local control of patients with stage pT3-4N0-3M0 ESCC. However, distant metastasis was the main failure pattern after receiving PORT. Further studies need to be conducted to control hematogenous metastasis in the future.

INTRODUCTION
============

Esophageal cancer is an aggressive malignancy with high morbidity and mortality\[[@B1]\]. The guidelines of the National Comprehensive Cancer Network\[[@B2]\] recommend that esophagectomy is still the primary choice for esophageal cancer. Neoadjuvant chemoradiotherapy followed by surgery is the standard care for patients with locally advanced esophageal squamous cell carcinoma (ESCC)\[[@B3]\]. Nevertheless, many patients tend to choose surgery as their primary treatment because of the traditional concept in China, although neoadjuvant therapy is recommended by surgeons. Furthermore, most patients who were clinically diagnosed with stage T1-2 disease were pathologically confirmed as having stage T3-4 after surgery owing to the less frequent use of ultrasound endoscopy. However, with a poor survival and high rate of recurrence after esophagectomy\[[@B4],[@B5]\], patients with pT3-4 disease require multidisciplinary adjuvant treatments. Additionally, the efficacy of postoperative radiotherapy (PORT) has been investigated widely. Based on a cancer registry database, patients with esophageal cancer could not benefit from PORT\[[@B6]\]. However, many retrospective studies showed that PORT could apparently improve the locoregional control rate and overall survival (OS) rate for patients with locally advanced ESCC (stage III or with positive lymph node)\[[@B7]-[@B9]\].

Locoregional recurrence is the most common pattern of failure after esophagectomy\[[@B4],[@B10]\]. Approximately 80% of recurrence sites of ESCC patients after curative esophagectomy are located in the supraclavicular and superior mediastinal lymph nodes, which are called the T-shape field\[[@B11]-[@B13]\]. Chen et al\[[@B7]\] reported that the locoregional recurrence rate for patients receiving PORT was significantly lower than that of patients who had undergone surgery alone. However, no study has compared the difference of the failure patterns between stage pT3-4 patients with or without PORT after esophagectomy.

In that case, this study was administered with the intention of investigating the difference in the failure patterns of patients with stage pT3-4N0-3M0 ESCC after complete resection with or without PORT and estimating whether patients could obtain a DFS benefit from PORT.

MATERIALS AND METHODS
=====================

Patients
--------

Patients in this study were screened from two treatment centers that included 429 ESCC patients with stage pT1-4N0-3M0. Patients in the S + R arm were screened from a prospective cohort that included 124 patients with stage pT3-T4 ESCC, who had received radiotherapy after surgery\[[@B14]\]. Patients in the S arm were screened from a retrospective cohort including 305 patients who had undergone radical surgery alone\[[@B12]\]. The main eligible inclusion criteria were as follows: (1) A diagnosis of primary thoracic ESCC and pathologically confirmed stage T3-4N0-3M0 disease; (2) Aged 18-75 years; (3) Integrated physical examination, contrast esophagography, enhanced computed tomography of the chest and upper abdomen, and external ultrasonography of the neck or positron emission tomography (PET/CT) conducted before surgery and radiotherapy; (4) Adequate bone marrow, liver and renal functions for patients receiving radiotherapy; and (5) Patients with any patterns of failure during follow-up. The exclusion criteria were as follows: Receiving chemotherapy or radiotherapy before surgery; no failure patterns occurring to the last follow-up; patients with a secondary primary tumor after or during PORT. Additionally, patients who had received adjuvant chemotherapy were not considered in the study. The patient selection procedure is shown in Figure [1](#F1){ref-type="fig"}.

![Patient selection flow chart. ESCC: Esophageal squamous cell carcinoma; PORT: Postoperative radiotherapy.](WJGO-11-1172-g001){#F1}

Radiotherapy
------------

All the patients in the S + R arm received radiotherapy within 8 wk after surgery. The patients underwent CT-based treatment simulation in the supine position with a thermoplastic mask for immobilization. Five-millimeter-thick images were obtained from the entire neck to the upper abdomen. Intensity-modulated radiotherapy with a 6 MV X-ray linear accelerator was used for external beam radiation. The delineation of the clinical tumor volume (CTV) was based on surgery procedure, CT imaging obtained before and after surgery, and gastrointestinal endoscopy obtained before treatment. The CTV included the primary tumor bed and metastatic lymph nodes or plus bilateral supraclavicular and upper-middle mediastinal lymphatic drainage areas (T-shape field). The planning target volume was defined as CTV plus a 0.8 to 1.0 cm margin. The radiation dose to the primary tumor bed and metastatic lymph nodes was 63 Gy (2.25 Gy/day/fraction, 28 fractions) for patients with stage T4 or 60.2 Gy (2.15 Gy/day /fraction, 28 fractions) for patients with stage T3 disease. The lymphatic drainage area was prescribed a dose of 50.4 Gy (1.8 Gy/day/fraction, 28 fractions). The prescription dose was delivered to the target volume mainly through the mediastinum. Normal tissue dose constraints met the usual requirements: (1) Maximum spinal cord dose ≤ 45 Gy; (2) Lung V20 ≤ 25% and mean lung dose ≤ 15 Gy; and (3) Mean heart dose ≤ 30 Gy.

Chemotherapy
------------

After surgery or radiotherapy was completed, chemotherapy was scheduled intravenously with cisplatin (25 mg/m^2^/d, d1--3) and 5-fluorouracil (5-Fu, 600 mg/m^2^/d, d1--5) or paclitaxel (135-175 mg/m^2^/d, d1) for four cycles with an interval of 3-4 wk.

Follow-up
---------

Follow-up visits were administered every 3 mo for the first two years after treatment, every 6 mo for the next three years, and then once a year thereafter. Patients in the S + R arm were followed to March 2017. Follow-up investigations included hematological examination, supraclavicular lymph node ultrasonography, contrast esophagography, and enhanced computed tomography of the chest and upper abdomen. When necessary, PET/CT or bone emission computed tomography was required.

Definitions of failure patterns
-------------------------------

This study analyzed the first failure pattern only. The discovery of relapse was mainly based on imaging features. Fine-needle aspiration biopsy and PET/CT were implemented only when necessary. Locoregional recurrence included the tumor bed area, anastomotic stoma relapse, and regional lymph nodes, for which the short axis diameter was at least 1 cm in the CT image, according to the tumor location. Distant metastasis was defined as neoplasms occurring in organs or non-regional lymph node metastasis. The definitions of failure patterns were described in detail in our previous report\[[@B12]\]. Recurrence comprising locoregional and distant failure simultaneously was classified as mixed failure.

Statistical analysis
--------------------

Owing to the retrospective characteristics of the S arm, we did not have access to the OS information of over 10% patients. The primary endpoint of this study was to compare the difference in the failure patterns between the two arms. The secondary endpoint was to evaluate whether patients with locally advanced ESCC could achieve DFS benefit from PORT. DFS was calculated from the date of surgery to the date that any type of failure occurred or the date of the last follow-up. The difference in the failure patterns and clinical characteristics was calculated by the Chi-squared test or Fisher's exact test. The Kaplan-Meier method was used to evaluate the difference in DFS between the two arms. The log-rank test was used to determine the statistical significance of the difference. Univariate analysis and multivariate analysis (Cox proportional hazard regression model) were performed to evaluate the risk factors associated with the prognosis. A *P* value less than 0.05 (two sided) was considered statistically significant. All statistical analyses were calculated with SPSS (version 22.0 IBM Chicago, United States).

RESULTS
=======

This study included 230 patients. In the prospective cohort of 124 ESCC patients with stage pT3-T4 disease who underwent PORT, 66 patients lived free of disease and 2 patients with secondary primary tumor were excluded. Finally, 56 patients who met the criteria were recruited as the S + R arm from April 2011 to February 2016. We retrospectively screened 305 patients who received surgery alone. Among them, 131 patients with stage pT1-2 disease were excluded and 174 patients with pT3-4 disease suffering failure were enrolled as the S arm from July 2006 and October 2014. Finally, 230 patients were included in this study. All patients in the S + R arm completed the intended radiotherapy treatment plan within 6 wk. There were 60.7% of patients who received sequential chemotherapy after radiotherapy was completed. Others who declined or could not tolerate did not receive chemotherapy. There was no difference in the percentage of patients receiving chemotherapy between the S arm and S + R arm. The baseline clinical and pathologic characteristics of the two arms are shown in Table [1](#T1){ref-type="table"}. Differences between the two cohorts in sex, age, pathological differentiation, number of lymph nodes dissected, lymph node involvement, and chemotherapy were not significant, except for tumor location (*P* = 0.031).

###### 

Clinical and pathological characteristics of patients of the two arms, *n* (%)

  **Variable**                   **S arm (*n* = 174)**   **S + R arm (*n* = 56)**   ***P* value**
  ------------------------------ ----------------------- -------------------------- ---------------
  Sex                                                                               0.656
  Male                           159 (91.4)              49 (87.5)                  
  Female                         15 (8.6)                7 (12.5)                   
  Age (yr)                                                                          0.056
  \<60                           106 (60.9)              42 (75.0)                  
  ≥60                            68 (39.1)               14 (25.0)                  
  Pathological differentiation                                                      0.586
  Poor                           66 (37.5)               1 (1.8)                    
  Moderate                       97 (55.7)               33 (58.9)                  
  Well                           10 (5.7)                22 (39.3)                  
  Tumor location                                                                    0.031a
  Upper                          15 (8.6)                3 (5.4)                    
  Middle                         98 (56.3)               22 (39.3)                  
  Lower                          61 (35.1)               31 (55.4)                  
  Lymph node dissection                                                             0.448
  2-field resection              139 (79.9)              49 (87.5)                  
  3-field resection              28 (16.1)               7 (12.5)                   
  No. of LNs involved                                                               0.740
  ≤2                             113 (64.9)              35 (62.5)                  
  ≥3                             61 (35.1)               21 (37.5)                  
  No. of LNs dissected                                                              0.569
  \<12                           2 (1.1)                 1 (1.8)                    
  ≥12                            172 (98.9)              55 (98.2)                  
  T stage                                                                           0.075
  T3                             164 (94.3)              48 (85.7)                  
  T4                             10 (5.7)                8 (14.3)                   
  Chemotherapy                                                                      0.978
  Yes                            106 (60.9)              34 (60.7)                  

^a^*P* \< 0.05. S arm: Surgery alone arm; S + R arm: Surgery + postoperative radiotherapy arm; LN: Lymph node.

Failure patterns
----------------

All patients included in this study developed failure during the follow-up. We compared the difference in the constituent ratio of the failure patterns between the two arms. As shown in Table [2](#T2){ref-type="table"}, the difference in the failure patterns between the two arms was statistically significant (*P* \< 0.001). Regarding patients with distant metastasis, locoregional recurrence, and mixed failure, 64.3%, 25.0%, and 10.7%, respectively, were in the S + R arm and 8.0%, 81.0%, and 11.0%, respectively, were in the S arm. Patients in the S arm had a significantly higher proportion of locoregional recurrence than patients in the S + R arm (92.0% *vs* 35.7%, respectively, *P* \< 0.001). However, patients in the S + R arm had a much higher proportion of distant metastasis than patients in the S arm (75.0% *vs* 19.0%, *P* \< 0.001). The most common regions for locoregional recurrence were the supraclavicular and mediastinal lymph nodes (29.5% and 48.3%, respectively) for the surgery cohort. For the S + R arm, supraclavicular lymph nodes (9/17 patients) were the most common relapse region after PORT. The lungs, liver, and bone \[41.7% (14/36 patients), 19.4% (7/36 patients), and 16.7% (6/36 patients), respectively\] were the most common metastatic organs for the S + R arm. Distant metastasis mainly occurred in the lungs (7/33), supraclavicular lymph nodes (16/33), and celiac lymph nodes (10/33) for the S arm (Figure [2](#F2){ref-type="fig"}).

###### 

Comparison of failure patterns for the two arms, *n* (%)

  **Type of failure**       **S arm *(n* = 174)**   **S + R arm *(n* = 56)**   ***P* value**
  ------------------------- ----------------------- -------------------------- ---------------
  Failure patterns                                                             \< 0.001
  Distant metastasis        14 (8.0)                36 (64.3)                  
  Locoregional recurrence   141 (81.0)              14 (25.0)                  
  Mixed failure             19 (11.0)               6 (10.7)                   
  Distant metastasis                                                           \< 0.001
  Distant metastasis        33 (19.0)               42 (75.0)                  
  Others                    141 (81.0)              14 (25.0)                  
  Locoregional failure                                                         \< 0.001
  Locoregional recurrence   160 (92.0)              20 (78.3)                  
  Others                    14 (8.0)                36 (21.7)                  

S arm: Surgery alone arm; S + R arm: Surgery + postoperative radiotherapy arm; LN: Lymph node.

![Details of the failure patterns for the two arms. The Y axis represents the number of patients. The most common regions for locoregional recurrence were the supraclavicular and mediastinal lymph nodes (29.5% and 48.3%, respectively) for the surgery cohort. For the S + R arm, supraclavicular lymph nodes (9 of 17 patients) were the most common relapse region after postoperative radiotherapy.](WJGO-11-1172-g002){#F2}

DFS
---

Recurrence occurred almost within two years for both arms. The 1-, 2-, and 3-year DFS rates of the S arm and S + R arm were 33.7%, 14.5%, and 4.7% and 51.8%, 26.8%, and 8.9%, respectively. The DFS was improved from 8 mo to 12.7 mo after receiving PORT. The difference in DFS for the two arms was marginally significant (*P* = 0.048, Figure [3](#F3){ref-type="fig"}).

![Disease-free survival (174 *vs* 56) of patients in the two arms. The Y axis represents disease-free survival (DFS) rate. The median DFS rates of the S and S + R arm were 8.0 and 12.7 mo, respectively.](WJGO-11-1172-g003){#F3}

Univariate analysis revealed that only lymph node involvement was associated with DFS for T3-4 ESCC patients (*P* \< 0.001, Figure [4](#F4){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Patients with the number of lymph node metastases fewer than 2 could achieve a better DFS (11.0 *vs* 8.0 mo). DFS was not statistically associated with age, sex, tumor location, pathological differentiation, lymph node dissection, number of lymph nodes dissected, and adjuvant chemotherapy.

###### 

Univariate and multivariate analyses for factors affecting survival

                                 **Univariate analysis**   **Multivariate analysis**                                    
  ------------------------------ ------------------------- --------------------------- ---------- --------------------- -----------------------------------------
  Sex                                                                                             0.841 (0.532-1.328)   0.457
  Male                           9.5                       0.309                       0.579                            
  Female                         8                                                                                      
  Age (yr)                                                                                        0.712 (0.530-0.957)   0.024
  \< 60                          9                         1.023                       0.312                            
  ≥ 60                           9.5                                                                                    
  Pathological differentiation                                                                    1.128 (0.094-1.934)   0.071
  Poor                           8                         6.377                       0.095                            
  Moderate                       10.4                                                                                   
  Well                           9.5                                                                                    
  Tumor location                                                                                  1.423 (0.849-2.386)   0.363
  Upper                          6.6                       3.277                       0.194                            
  Middle                         9.9                                                                                    
  Lower                          8.8                                                                                    
  Lymph node dissection                                                                           0.531 (0.222-1.186)   0.107
  2-field resection              9                         3.462                       0.177                            
  3-field resection              8                                                                                      
  No. of LNs involved                                                                             1.843 (1.369-2.482)   \<0.001[a](#T3FN1){ref-type="table-fn"}
  ≤ 2                            11                        13.483                      \< 0.001                         
  ≥ 3                            8                                                                                      
  No. of LN dissected                                                                             1.460 (0.459-4.644)   0.522
  \< 12                          7                         0.656                       0.418                            
  ≥ 12                           9.5                                                                                    
  Chemotherapy                                                                                    0.732 (0.552-0.971)   0.031
  Yes                            8                         1.769                       0.183                            
  No                             10                                                                                     
  T stage                                                                                         0.697 (0.441-1.124)   0.132
  T3                             9                         0.087                       0.767                            
  T4                             8                                                                                      
  Radiotherapy                   \-                        \-                          \-         0.667 (0.487-0.915)   0.012[a](#T3FN1){ref-type="table-fn"}

*P* \< 0.05 in both univariate and multivariate analysis. S arm: Surgery alone arm; S + R arm: Surgery + postoperative radiotherapy arm; LN: Lymph node.

![Univariate analysis. The Y axis represents disease-free survival rate. Patients with fewer than two lymph nodes involved could achieve a better disease-free survival.](WJGO-11-1172-g004){#F4}

However, multivariate analysis indicated that the number of lymph node metastases ≥ 3 (HR = 1.843, 95%CI: 1.369-2.482; *P* \< 0.001), PORT (HR = 0.667, 95%CI: 0.487-0.915; *P* = 0.012), age (HR = 0.712, 95%CI: 0.530-0.957; *P* = 0.024), and chemotherapy (HR = 0.732, 95%CI: 0.552-0.971; *P* = 0.031) were independent prognostic factors for DFS in patients with stage pT3-4N0-3M0 ESCC (Table [3](#T3){ref-type="table"}).

DISCUSSION
==========

Although many studies have investigated the characteristics of failure patterns for patients with thoracic esophageal carcinoma after esophagectomy, this study is the first to investigate the difference in the failure patterns for stage pT3-4 ESCC patients with or without PORT after radical surgery. Our study found that radiotherapy following esophagectomy was more effective in improving DFS and decreasing locoregional recurrence of patients with stage pT3-4 ESCC. Distant metastasis was the most common failure after receiving PORT. The number of lymph nodes involved over 3, radiotherapy, age, and chemotherapy were significantly associated with disease progression for patients with stage pT3-4 ESCC.

It is known that neoadjuvant chemoradiotherapy is recommended as the standard care for locally advanced ESCC. However, many patients initially diagnosed with T1-2N0 disease before surgery were finally diagnosed as having pT3-4N0-3M0 disease after surgery. Do these patients need to receive adjuvant treatment after surgery? Xiao et al\[[@B15]\] revealed that patients receiving PORT with a prescription dose of 60 Gy could obtain a local control benefit and a higher 5-year OS than patients receiving surgery alone. With the application of 3-dimentional conformality radiotherapy, PORT could bring both local control and OS benefit for patients with stage III and stage T3N0M0 esophageal cancer or patients with positive lymph nodes\[[@B16]-[@B19]\]. Additionally, Schreiber et al\[[@B18]\] reported a survival benefit for patients with both stage III ESCC and esophageal adenocarcinoma after receiving PORT. Our result also revealed a better DFS for patients in the S + R arm than those in the S arm.

It is common for patients with esophageal cancer to develop relapse after treatment. Locoregional failure is the most common failure pattern for patients with surgery alone; and mediastinal lymph nodes, especially the upper mediastinal lymph nodes and supraclavicular lymph nodes, are the most common recurrence sites\[[@B11]-[@B13],[@B20]\]. This study also showed that approximately 80% of cases with locoregional failure occurred in the T-shape field. By comparing the constituent ratio of failure patterns for patients who underwent surgery with or without PORT, it was showed that locoregional recurrence decreased and distant metastasis became the main failure pattern after receiving PORT for patients with stage T3-4 disease, a finding that agrees with the previous study results\[[@B7],[@B21]\]. Distant metastasis after receiving PORT is a new issue that leads to treatment failure. Considering that no difference was found in the survival of patients receiving adjuvant chemotherapy, whether chemotherapy could further decrease the rate of metastasis needs further research. The reasons that more patients showed distant metastasis may be due to the small number of patients, local control increase, or there were inherent factors making patients prone to distant metastasis. Our recent research identified a potential biomarker for metastasis of ESCC\[[@B22]\], and we will study this topic further to clarify the mechanism of increased distant metastasis after PORT.

Both univariate and multivariate analyses demonstrated that lymph node involvement was significantly associated with the DFS of patients with stage T3-4 disease. Adjuvant chemotherapy may be a favorable factor. Meanwhile, many studies have reported that adjuvant chemotherapy could improve local control and OS or DFS, especially for patients with positive lymph nodes\[[@B23],[@B24]\]. Researchers also reported that postoperative chemoradiotherapy could decrease both locoregional and distant recurrence. However, it must be noted that combined chemoradiation therapy may lead to higher toxicity\[[@B25]\]. Thus, we supposed that combined radiation and chemotherapy sequentially may be effective in improving DFS or even OS.

This study possessed some limitations. First, due to the retrospective nature of this study, it is inevitable that some information was uncontrolled or missed and it is difficult to address some biases. A perspective study should be conducted to answer these questions in the future. Second, patients in the S + R arm were fewer than those in the S arm, possibly influencing DFS; a longer follow-up and more enrolled patients are needed. Third, the study compared the constituent ratio of failure patterns because of the respective characteristics of patients.

In conclusion, PORT could improve DFS and decrease the locoregional recurrence of patients with stage pT3-4N0-3M0 ESCC. However, distant metastasis is the main failure pattern in patients after receiving PORT. Further study needs to be conducted to evaluate how to control hematogenous metastasis.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Postoperative radiotherapy (PORT) could improve the local control of stage T3-4 or lymph node positive esophageal squamous cell carcinoma (ESCC) patients. There was no study comparing the difference of failure patterns after surgery with or without PORT in such patients.

Research motivation
-------------------

We wanted to investigate the difference of failure patterns in order to guide the following treatment for patients suffering treatment relapse.

Research objectives
-------------------

To define the difference between patients with stage pT3-4N0-3M0 ESCC with or without PORT after esophagectomy.

Research methods
----------------

Patients with pathologically stage T3-4 ESCC who receive PORT after surgery were included in an S + R arm, and the others without PORT were included in an S arm. This study mainly investigated the difference of failure patterns between the two arms.

Research results
----------------

This study reported that PORT could decrease locoregional relapse. However, the proportion of distant metastasis in the S + R arm was much more than that in the S arm.

Research conclusions
--------------------

PORT could improve the local control for patients with stage pT3-4 ESCC. Further studies need to be conducted to control hematogenous metastasis.

Research perspectives
---------------------

The treatment of locally advanced ESCC is a hot topic. PORT could decrease locoregional lymph node relapse, but distant metastasis after PORT is the main reason that results in treatment failure. It is urgent to find an effective treatment to control this situation. And now we should explain the main failure patterns after undergoing different treatment strategies.
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